Abstract: A semiconductor device includes a peripheral circuit structure; a lower stack disposed on the peripheral circuit structure and an upper stack disposed in the lower stack including a plurality of lower insulating layers and a plurality of lower word lines alternately stacked with the lower insulating layers; a plurality of channel structures extending through the lower stack and the upper stack in the cell array area; a pair of separation insulating layers extending vertically through the lower stack and the upper stack and extending in a horizontal direction, the pair of separation insulating layers being spaced apart from each other in a vertical direction; and a word line separation layer disposed at an upper portion of the lower stack and crossing the pair of separation insulating layers when viewed in a plan view, the word line separation layer extending vertically through at least one of the lower word lines.

Abstract: This invention relates to a curable composition for forming high refractive index optical material and optical material comprising the same, and more specifically, to a curable composition for forming high refractive index optical material comprising an episulfide compound and a sulfur-containing polymer compound, and optical material comprising the same.

Abstract: A three-dimensional semiconductor memory device may include a first stack block including first stacks arranged in a first direction on a substrate, a second stack block including second stacks arranged in the first direction on the substrate, and a separation structure provided on the substrate between the first stack block and the second stack block. The separation structure may include first mold layers and second mold layers, which are stacked in a vertical direction perpendicular to a top surface of the substrate.

Abstract: This invention relates to the oral pharmaceutical composition of metformin and rosuvastatin. In detail, this invention comprising metformin, rosuvastatin, sustained release carriers and/or excipients reduces the side effects caused by statins and enhances safety, patients' convenience and compliance with its one-per-day dosage. In addition, regulation of an early effective blood concentration of the drug and maintenance of the drug's concentration at a steady level in vivo by a controlled-release can be advantageously used as a pharmaceutical composition for preventing and treating hyperlipidemia.